Sexual behaviour among women using intramuscular depot medroxyprogesterone acetate, a copper intrauterine device, or a levonorgestrel implant for contraception: Data from the ECHO randomized trial
- PMID: 38722832
- PMCID: PMC11081305
- DOI: 10.1371/journal.pone.0299802
Sexual behaviour among women using intramuscular depot medroxyprogesterone acetate, a copper intrauterine device, or a levonorgestrel implant for contraception: Data from the ECHO randomized trial
Abstract
Background: Contraceptive use has complex effects on sexual behaviour and mood, including those related to reduced concerns about unintended pregnancy, direct hormonal effects and effects on endogenous sex hormones. We set out to obtain robust evidence on the relative effects of three contraceptive methods on sex behaviours, which is important for guiding contraceptive choice and future contraceptive developments.
Methods: This is a secondary analysis of data from the Evidence for Contraceptive Options and HIV Outcomes (ECHO) randomized trial in which 7,829 HIV-uninfected women from 12 sites in Eswatini, Kenya, South Africa and Zambia seeking contraception were randomly assigned to intramuscular depot-medroxyprogesterone acetate (DMPA-IM), the copper intrauterine device (Cu-IUD) or the levonorgestrel (LNG) implant. Data collected for 12 to 18 months using 3-monthly behavioural questionnaires that relied on recall from the preceding 3 months, were used to estimate relative risk of post-baseline sex behaviours, as well as sexual desire and menstrual bleeding between randomized groups using modified Poisson regression.
Results: We observed small but generally consistent effects wherein DMPA-IM users reported lower prevalence of specified high risk sexual behaviours than implant users than Cu-IUD users (the '>' and '<' symbols indicate statistically significant differences): multiple sex partners 3.6% < 4.8% < 6.2% respectively; new sex partner 3.0% < 4.0% <5.3%; coital acts 16.45, 16.65, 17.12 (DMPA-IM < Cu-IUD); unprotected sex 65% < 68%, 70%; unprotected sex past 7 days 33% <36%, 37%; sex during vaginal bleeding 7.1%, 7.1% < 8.9%; no sex acts 4.1%, 3.8%, 3.4% (DMPA-IM > Cu-IUD); partner has sex with others 10% < 11%, 11%. The one exception was having any sex partner 96.5%, 96.9% < 97.4% (DMPA-IM < Cu-IUD). Decrease in sexual desire was reported by 1.6% > 1.1% >0.5%; amenorrhoea by 49% > 41% >12% and regular menstrual pattern by 26% <35% < 87% respectively.
Conclusions: These findings suggest that women assigned to DMPA-IM may have a modest decrease in libido and sexual activity relative to the implant, and the implant relative to the Cu-IUD. We found more menstrual disturbance with DMPA-IM than with the implant (and as expected, both more than the Cu-IUD). These findings are important for informing the contraceptive choices of women and policymakers and highlight the need for robust comparison of the effects of other contraceptive methods as well.
Copyright: © 2024 Hofmeyr et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Conflict of interest statement
GJH has an interest in a blood loss monitoring device which is unrelated to this paper. JMB is an employee of Gilead Sciences, outside of the present work. JD joined Pfizer after the study was completed; and was previously with FHI 360. MSM, JB, PS, KKT, RI, IB, EM, CM, JD, JS, NP, TPP, KR, MO and TDM declare no conflict of interest. There are no patents, products in development or marketed products associated with this research to declare.
Figures
Similar articles
-
Effects of depot medroxyprogesterone acetate, the copper IUD and the levonorgestrel implant on testosterone, sex hormone binding globulin and free testosterone levels: ancillary study of the ECHO randomized clinical trial.BMC Womens Health. 2024 Mar 8;24(1):167. doi: 10.1186/s12905-024-02990-8. BMC Womens Health. 2024. PMID: 38459552 Free PMC article. Clinical Trial.
-
HIV incidence among women using intramuscular depot medroxyprogesterone acetate, a copper intrauterine device, or a levonorgestrel implant for contraception: a randomised, multicentre, open-label trial.Lancet. 2019 Jul 27;394(10195):303-313. doi: 10.1016/S0140-6736(19)31288-7. Epub 2019 Jun 13. Lancet. 2019. PMID: 31204114 Free PMC article. Clinical Trial.
-
Behavioral effects of different contraceptive methods and HIV acquisition: an ancillary study of the ECHO randomized trial.Reprod Health. 2021 Sep 29;18(1):192. doi: 10.1186/s12978-021-01232-6. Reprod Health. 2021. PMID: 34587971 Free PMC article. Clinical Trial.
-
Long-acting contraceptive options.Int J Fertil Menopausal Stud. 1996 Mar-Apr;41(2):69-76. Int J Fertil Menopausal Stud. 1996. PMID: 8829701 Review.
-
Canadian Contraception Consensus (Part 1 of 4).J Obstet Gynaecol Can. 2015 Oct;37(10):936-42. doi: 10.1016/s1701-2163(16)30033-0. J Obstet Gynaecol Can. 2015. PMID: 26606712 English, French.
Cited by
-
Serum norethisterone (NET) levels in NET-enanthate (NET-EN) injectable contraception users substantially interfere with testosterone immunoassay measurements and confound interpretation of biological outcomes.Contracept Reprod Med. 2025 Aug 19;10(1):51. doi: 10.1186/s40834-025-00388-x. Contracept Reprod Med. 2025. PMID: 40830906 Free PMC article.
References
-
- Malmborg A, Brynte L, Falk G, Brynhildsen J, Hammar M, Berterö C. Sexual function changes attributed to hormonal contraception use—a qualitative study of women experiencing negative effects. Eur J Contracept Reprod Health Care. 2020. Jun;25(3):169–175. doi: 10.1080/13625187.2020.1736545 - DOI - PubMed
-
- Hofmeyr GJ, Singata-Madliki M, Lawrie TA, Bergel E, Temmerman M. Effects of the copper intrauterine device versus injectable progestin contraception on pregnancy rates and method discontinuation among women attending termination of pregnancy services in South Africa: a pragmatic randomized controlled trial. Reprod Health. 2016. Apr 18;13(1):42. doi: 10.1186/s12978-016-0153-9 - DOI - PMC - PubMed
-
- Hofmeyr GJ, Singata-Madliki M, Lawrie TA, Bergel E, Temmerman M. Effects of injectable progestogen contraception versus the copper intrauterine device on HIV acquisition: sub-study of a pragmatic randomised controlled trial. J Fam Plann Reprod Health Care. 2017. Jul;43(3):175–180. doi: 10.1136/jfprhc-2016-101607 - DOI - PMC - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Miscellaneous